A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Topically-applied AG013 for the Attenuation of Oral Mucositis in Subjects With Cancers of the Head and Neck Receiving Concomitant Chemoradiation Therapy
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2017
At a glance
- Drugs AG 013 (Primary)
- Indications Stomatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Oragenics Inc
- 09 Nov 2017 According to an Intrexon Corporation media release, the first patient has been dosed in this trial.
- 31 Aug 2017 According to an Oragenics media release, first patient has been dosed.
- 28 Jul 2017 Status changed from planning to recruiting.